| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083136 | Drug Discovery Today: Therapeutic Strategies | 2006 | 8 Pages |
Abstract
The first marketed glycylcycline antibacterial agent, tigecycline (Tygacil™, Wyeth Research), received Food and Drug Administration (FDA) approval in 2005 for use in patients with complicated skin and skin-structure infections and complicated intra-abdominal infections. As an expanded broad-spectrum agent with Gram-negative and Gram-positive coverage, including resistant pathogens, tigecycline has arrived at a crucial time and will provide an excellent option for empiric use in the clinic.
Section editors:Gary Woodnutt – CovX, San Diego, USAPaul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
C. Hal Jones, Peter J. Petersen,